SEARCH RESULTS FOR:
Tom McCulley
CEO, ANGLO AMERICAN PERU
Anglo American provide an update on progress at its huge Quellaveco mine in Peru.
George Kwatia
PARTNER, PWC GHANA
MACIG West Africa 2020-2021
PwC Ghana comments on how the mining industry and the Ghanian government are managing the impacts of the pandemic.
Osam Iyahen
SENIOR DIRECTOR NATURAL RESOURCES, AFRICA FINANCE CORPORATION
MACIG West Africa 2020-2021
Africa Finance Corporation explains its role of investing in infrastructure across Africa in order to both assist and benefit from the growth that this will engender.
Jake Klein
EXECUTIVE CHAIRMAN, EVOLUTION MINING
Evolution Mining explains the changes it has made to the Red Lake mine.
Jose Vizquerra
PRESIDENT & CEO, O3 MINING
Jose Vizquerra discusses O3 Mining’s PEA for Marban, and exploration plans for 2021.
Will Coetzer & Jane Banks
MANAGING PARTNER & PRINCIPAL CONSULTANT, STRATUM INTERNATIONAL
MACIG West Africa 2020-2021
Stratum International explains the shifts in the mining industry recruitment patterns.
Ray Shorrocks
EXECUTIVE CHAIRMAN, AUTECO MINERALS
Ray Shorrocks explains how the team behind Auteco Minerals hopes to replicate the success it had at Bellevue Gold.
Dean McPherson
HEAD, BUSINESS DEVELOPMENT – GLOBAL MINING, TORONTO STOCK EXCHANGE AND TSX VENTURE EXCHANGE
A discussion about trends impacting mining companies listed on Toronto’s exchanges.
John Kwofie & Ivan Doku
PRINCIPAL MINING ENGINEER AND COUNTRY MANAGER & PRINCIPAL RESOURCE GEOLOGIST AND COUNTRY MANAGER-DESIGNATE, SRK CONSULTING
MACIG West Africa 2020-2021
An overview of the firm’s activities in West Africa.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
